(Rac)-Modipafant UK-74505|cas:122956-68-7|西域试剂

(Rac)-Modipafant UK-74505,98.15%

产品编号：Bellancom-108908| CAS NO：122956-68-7| 分子式：C₃₄H₂₉ClN₆O₃| 分子量：605.09

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-108908		￥8500.00	杭州北京（现货）
Bellancom-108908		￥14500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

(Rac)-Modipafant UK-74505

产品介绍

(Rac)-Modipafant (UK-74505) 是一种口服的、选择性的、长效的不可逆血小板活化因子受体 (PAFR) 受体拮抗剂。(Rac)-Modipafant 预防严重登革热感染。

生物活性

(Rac)-Modipafant (UK-74505) is an orally active, selective, long-acting irreversible platelet activating factor receptor (PAFR) antagonist. (Rac)-Modipafant prevents dengue infection.

体外研究

体内研究

(Rac)-Modipafant (UK-74505) (10 mg/kg; p.o.; twice a day until day 10) prevents Severe Dengue Infection.
(Rac)-Modipafant exhibits highly selective, time-dependent inhibition of PAF-induced aggregation of rabbit washed platelets (IC₅₀=26.3 and 1.12 nM after 0.25 and 60 min preincubation, respectively)^[4].
(Rac)-Modipafant (5-20 mg/kg; p.o.) dose-dependently inhibits the Zymosan -induced articular hyperalgesia^[5].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	8- to 10-week-old BALB/c mice (DEN-2 strain infected)
Dosage:	10 mg/kg
Administration:	P.o.; twice a day (started on days 0, 3, 5, or 7) until day 10
Result:	Decreased by approximately 50% the lethality associated with DEN-2 infection.

Animal Model:	Male BALB/C (8- to 10- week-old) wild-type mice^[5]
Dosage:	5, 10 and 20 mg/kg
Administration:	P.o.
Result:	Dose-dependently inhibited the Zymosan -induced articular hyperalgesia.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	8- to 10-week-old BALB/c mice (DEN-2 strain infected)
Dosage:	10 mg/kg
Administration:	P.o.; twice a day (started on days 0, 3, 5, or 7) until day 10
Result:	Decreased by approximately 50% the lethality associated with DEN-2 infection.

Animal Model:	Male BALB/C (8- to 10- week-old) wild-type mice^[5]
Dosage:	5, 10 and 20 mg/kg
Administration:	P.o.
Result:	Dose-dependently inhibited the Zymosan -induced articular hyperalgesia.

性状

Solid

溶解性数据

In Vitro:

DMSO : 50 mg/mL (82.63 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.6526 mL	8.2632 mL	16.5265 mL
5 mM	0.3305 mL	1.6526 mL	3.3053 mL
10 mM	0.1653 mL	0.8263 mL	1.6526 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (4.13 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.13 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液